Sugi Predict

Sugi Predict / Compounds / SCHEMBL20517628

SCHEMBL20517628

SCHEMBL20517628

COC(=O)c1cc(Br)n[nH]1

nearest known ligand 0.65

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.65
▸ GAA P10253 1/20 0.54
▸ ALPL P05186 11/20 0.53
▸ MAPT P10636 6/20 0.53
▸ RAB9A P51151 3/20 0.53
▸ POLB P06746 1/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ NPC1 O15118 2/20 0.51
▸ LMNA P02545 1/20 0.51
▸ CYP1A2 P05177 1/20 0.46
▸ XDH P47989 1/20 0.45
▸ HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30107039 0.81 MAPK1 (0.70) MAPK1GAAALPLMAPTRAB9A
SCHEMBL17593138 0.80 ALPL (0.55) MAPK1GAAALPLMAPTRAB9A
SCHEMBL171413 0.78 MAPK1 (0.67) MAPK1GAAALPLMAPTRAB9A
SCHEMBL285996 0.78 MAPK1 (0.67) MAPK1GAAALPLMAPTRAB9A
SCHEMBL68056 0.78 MAPK1 (1.00) MAPK1GAAALPLMAPTRAB9A
SCHEMBL21630583 0.77 MAPK1 (0.65) MAPK1GAAALPLMAPTRAB9A
SCHEMBL286531 0.77 MAPK1 (0.65) MAPK1GAAALPLMAPTRAB9A
SCHEMBL30614240 0.77 MAPK1 (0.96) MAPK1GAAALPLMAPTRAB9A
SCHEMBL1812854 0.76 MAPK1 (0.79) MAPK1GAAALPLMAPTRAB9A
SCHEMBL3171147 0.76 MAPK1 (0.62) MAPK1GAAALPLMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117024411-B Isoquinoline as HPK1 inhibitor 豪夫迈·罗氏有限公司 2026-05-19 — — CN disclosed
US-12630533-B2 Heterocyclic compounds useful as KCNT1 inhibitors ACTIO BIOSCIENCES, INC. (US) 2026-05-19 — — US disclosed
US-12617783-B2 Heterocyclic GLP-1R agonists BIOMEA FUSION, INC. (US) 2026-05-05 — — US disclosed
EP-4724437-A1 METHODS OF TREATING INFLAMMATORY DISEASES Interline Therapeutics, Inc. (US) 2026-04-15 — — EP disclosed
US-20260091026-A1 METHODS OF TREATING INFLAMMATORY DISEASES INTERLINE THERAPEUTICS INC (US) 2026-04-02 — — US disclosed
US-20260085073-A1 PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS INC (US) 2026-03-26 — — US disclosed
US-20260085082-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2026-03-26 — — US disclosed
EP-4705308-A1 EGFR INHIBITORS FOR TREATING DISEASE Blossomhill Therapeutics, Inc. (US) 2026-03-11 — — EP disclosed
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF BIOGEN MA INC (US) 2026-01-29 — — US disclosed
US-20260015350-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS MIRATI THERAPEUTICS INC (US) 2026-01-15 — — US disclosed
CN-107759574-B 5-fluoro-1H-pyrazole-3-formate intermediate and synthesis method thereof 南京药石科技股份有限公司 2020-07-03 — — CN disclosed
EP-3601284-A1 NAPHTHYRIDINES AS INHIBITORS OF HPK1 H. Hoffnabb-La Roche Ag (CH) 2020-02-05 — — EP disclosed
EP-3601259-A1 ISOQUINOLINES AS INHIBITORS OF HPK1 H. Hoffnabb-La Roche Ag (CH) 2020-02-05 — — EP disclosed
CN-110709392-A Isoquinoline as HPK1 inhibitors 豪夫迈·罗氏有限公司 2020-01-17 — — CN disclosed
CN-110678466-A Naphthyridines as HPK1 inhibitors 豪夫迈·罗氏有限公司 2020-01-10 — — CN disclosed
US-10407424-B2 Naphthyridines as inhibitors of HPK1 GENENTECH, INC. (US) 2019-09-10 — — US disclosed
US-20180282282-A1 ISOQUINOLINES AS INHIBITORS OF HPK1 GENENTECH, INC. (US) 2018-10-04 — — US disclosed
US-20180282328-A1 NAPHTHYRIDINES AS INHIBITORS OF HPK1 GENENTECH, INC. (US) 2018-10-04 — — US disclosed
WO-2018183964-A1 ISOQUINOLINES AS INHIBITORS OF HPK1 GENENTECH, INC. (US) 2018-10-04 — — WO disclosed
WO-2018183956-A1 NAPHTHYRIDINES AS INHIBITORS OF HPK1 GENENTECH, INC. (US) 2018-10-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12617783-B2 Heterocyclic GLP-1R agonists GLP1R, GIPR, GPR119 MAPK1 1599/4885GAA 2858/4885ALPL 4520/4885
US-10407424-B2 Naphthyridines as inhibitors of HPK1 NEK1, NEK5, NEK11 MAPK1 828/4885GAA 1019/4885ALPL 2555/4885
US-20260085082-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM5C MAPK1 1740/4885GAA 3707/4885ALPL 3426/4885
US-12630533-B2 Heterocyclic compounds useful as KCNT1 inhibitors KCNT1, KCNT2, KCNJ2 MAPK1 2203/4885GAA 3225/4885ALPL 4829/4885
US-20180282282-A1 ISOQUINOLINES AS INHIBITORS OF HPK1 HIPK1, HPGDS, IP6K1 MAPK1 516/4885GAA 2293/4885ALPL 2736/4885
US-20180282328-A1 NAPHTHYRIDINES AS INHIBITORS OF HPK1 NEK1, NEK5, NEK11 MAPK1 828/4885GAA 1019/4885ALPL 2555/4885
US-20260091026-A1 METHODS OF TREATING INFLAMMATORY DISEASES NR3C1, NR3C2, CCR1 MAPK1 2197/4885GAA 2801/4885ALPL 3681/4885
US-20260015350-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS KRAS, NRAS, HRAS MAPK1 375/4885GAA 4638/4885ALPL 4846/4885
US-20260085073-A1 PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY MALT1, BCL6, BCL3 MAPK1 1624/4885GAA 4403/4885ALPL 4635/4885
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF TYK2, ERBB2, ROS1 MAPK1 147/4885GAA 2592/4885ALPL 4855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.